Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance - Université de Lorraine Access content directly
Journal Articles International Heart Journal Year : 2021

Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance

Abstract

Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
Fichier principal
Vignette du fichier
Case Canrenoate Girerd.pdf (546.42 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03116131 , version 1 (20-01-2021)

Identifiers

Cite

Nicolas Girerd, Matthieu Aubry, Pierre Lantelme, Olivier Huttin, Patrick Rossignol. Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance. International Heart Journal, 2021, 62 (1), pp.193-196. ⟨10.1536/ihj.20-442⟩. ⟨hal-03116131⟩
76 View
174 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More